Inhibition of the endothelial cell activation by antithrombin in vitro

Summary

We examined whether antithrombin (AT) inhibits tumor necrosis factor (TNF)-α-induced endothelial cell activation to elucidate molecular mechanism(s) of the anti-inflammatory activity of AT. AT inhibited the increase in E-selectin expression in cultured human umbilical vein endothelial cells (HUVECs) stimulated with TNF-α. In contrast, chemically modified AT that lacks affinity for heparin did not. AT inhibited the TNF-αinduced interaction of NF-κB p65 with p300, a homologue of cAMP-responsive element binding protein (CREB)-binding protein (CBP). AT increased both intracellular levels of cAMP and binding of phosphorylated-CREB to DNA in HUVECs. Forskolin showed the inhibitory effect similar to that of AT and pretreatment of HUVECs with KT-5720, an inhibitor of protein kinase A, reversed the inhibitory effect of AT. These observations suggested that AT inhibited the TNF-α-induced increase in E-selectin expression in HUVECs by inhibiting the interaction of NF-κB with CBP/p300 through cAMP-dependent protein kinase A-induced CREB activation. This inhibitory activity of AT might depend on its binding to heparin-like substances on the endothelial cell. Such an inhibitory effect of AT on TNF-α-induced endothelial cell activation might at least partly contribute to its anti-inflammatory activity.

Keywords

Antithrombin - E-selectin - cAMP - protein kinase A - CREB-binding protein/p300

• References

• 1 Abraham E. Coagulation abnormalities in acute lung injury and sepsis. Am J Respir Cell Mol Biol 2000; 22: 401-4.
• 2 Ware LB, Matthay MA. The acute respiratory distress syndrome. N Engl J Med 2000; 342: 1334-49.
• 3 Bevilacqua MP, Pober JS, Majeau GR. et al. Recombinant tumor necrosis factor in-duces procoagulant activity in cultured human vascular endothelium: Characterization and comparison with the actions of interleukin 1. Proc Natl Acad Sci U S A 1986; 83: 4533-7.
• 4 Zimmerman GA, Albertine KH, Carveth HJ. et al. Endothelial activation in ARDS. Chest 1999; 116: 18S-24S.
• 5 Fox RB. Prevention of granulocyte-mediated oxidant lung injury in rats by a hydroxyl radical scavenger, dimethylthiourea. J Clin Invest 1984; 74: 1456-64.
• 6 Zimmerman BJ, Grangder DN. Reperfusioninduced leukocyte infiltration: role of elastase. Am J Physiol 1990; 259: H390-4.
• 7 De Luca LG, Johnson DR, Whitley MZ. et al. cAMP and tumor necrosis factor competitively regulate transcriptional activation through and nuclear factor binding to the cAMPresponsive element/activating transcription factor element of the endothelial leukocyte adhesion molecule-1 (E-selectin) promoter. J Biol Chem 1994; 269: 19193-6.
• 8 Read MA, Whitley MZ, Gupta S. et al. Tumor necrosis factor α-induced E-selectin expression is activated by the nuclear factor-κB and c-JUN N-terminal kinase/p38 mitogen-activated protein kinase pathways. J Biol Chem 1997; 272: 2753-61.
• 9 Whelan J, Ghersa P, Hooft van Huijsduijnen R. et al. An NF-κB-like factor is essential but not sufficient for cytokine induction of endothelial cell adhesion molecule 1 (ELAM- gene transcription. Nucleic Acides Res 1991; 19: 2645-53.
• 10 Lewis H, Kaszubska W, DeLamarter JF. et al. Cooperativity between two NF-κB complexes, mediated by high-mobility-group protein I(Y), is essential for cytokine-induced expression of the E-selectin promoter. Mol Cell Biol 1994; 14: 5701-9.
• 11 Collins T, Read MA, Neish AS. et al. Transcriptional regulation of endothelial cell adhesion molecules: NF-κB and cytokineinducible enhancers. FASEB J 1995; 09: 899-909.
• 12 May MJ, Ghosh S. Signal transduction through NF-κB. Immunol Today 1998; 19: 80-8.
• 13 Widmann C, Gibson S, Jarpe MB. et al. Mitogen-activated protein kinase: conservation of a three-kinase module from yeast to human. Physiol Rev 1999; 79: 143-80.
• 14 Gerritsen ME, Williams AJ, Neish AS. et al. CREB-binding protein/p300 are transcriptional coactivators of p65. Proc Natl Acad Sci U S A 1997; 94: 2927-32.
• 15 Perkins ND, Felzien LK, Betts JC. et al. Regulation of NF-kappaB by cyclin-dependent kinases associated with the p300 coactivator. Science 1997; 275: 523-7.
• 16 Chrivia JC, Kwok RP, Lamb N. et al. Phosphorylated CREB binds specifically to the nuclear protein CBP. Nature 1993; 365: 855-9.
• 17 Kwok RP, Lundblad JR, Chrivia JC. et al. Nuclear protein CBP is a coactivator for the transcription factor CREB. Nature 1994; 370: 223-6.
• 18 Rosenberg RD. Biochemistry of heparin antithrombin interactions, and the physiological role of this natural anticoagulant mechanism. Am J Med 1989; 87: 2S-9S.
• 19 Taylor Jr FB, Emerson Jr TE, Jordan R. et al. Antithrombin-III prevents the lethal effects of escherichia coli infusion in baboons. Circ Shock 1988; 26: 227-35.
• 20 Warren BL, Eid A, Singer P. et al. Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA 2001; 286: 1869-78.
• 21 Uchiba M, Okajima K, Murakami K. et al. Attenuation of endotoxin-induced pulmonary vascular injury by antithrombin III. Am J Physiol 1996; 270: L921-30.
• 22 Uchiba M, Okajima K, Murakami K. Effects of various doses of antithrombin III on endotoxin-induced endothelial cell injury and coagulation abnormalities in rats. Thromb Res 1998; 89: 233-41.
• 23 Kaneider NC, Rabensteiner A, Reinisch CM. et al. Inhibition of human neutrophil chemotaxis toward interleukin 8 with six clinical antithrombin concentrates in vitro. Intensive Care Med 2002; 28: 1447-52.
• 24 Dunzendorfer S, Kaneider N, Rabensteiner A. et al. Cell-surface heparan sulfate proteoglycan-mediated regulation of human neutrophil migration by the serpin antithrombin III. Blood 2001; 97: 1079-85.
• 25 Oelschläger C, Römisch J, Staubitz A. et al. Antithrombin III inhibits nuclear factor κB activation in human monocytes and vascular endothelial cells. Blood 2002; 99: 4015-20.
• 26 Miller-Anderson M, Borg H, Anderson LO. Purification of antithrombin III by affinity chromatography. Thromb Res 1974; 05: 439-52.
• 27 Jaffe EA, Nachman RL, Becher CG. et al. Culture of human endothelial cells derived from umbilical cord veins. Identification by morphologic and immunologic criteria. J Clin Invest 1973; 52: 2745-56.
• 28 Uchiba M, Okajima K, Kaun C. et al. Gabexate mesilate, a synthetic anticoagulant, inhibits the expression of endothelial leukocyte adhesion molecules in vitro. Crit Care Med 2003; 31: 1147-53.
• 29 Yuksel M, Okajima K, Uchiba M. et al. Gabexate mesilate, a synthetic protease inhibitor, inhibits lipopolysaccharide-induced tumor necrosis factor-α production by inhibiting activation of both nuclear factor-κB and activator protein-1 in human monocytes. J Pharmacol Exp Ther 2003; 305: 298-305.
• 30 Goldbart A, Row BW, Kheirandish L. et al. Intermittent hypoxic exposure during light phase induces changes in cAMP response element binding protein activity in the rat CA1 hippocampal region: water maze performance correlates. Neuroscience 2003; 122: 585-90.
• 31 Delgado M, Munoz-Elias EJ, Kan Y. et al. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit tumor necrosis factor α transcriptional activation by regulating nuclear factor-κB and cAMP response element-binding protein/c-Jun. J Biol Chem 1998; 273: 31427-36.
• 32 Parry GCN, Mackman N. Role of cyclic AMP response element-binding protein in cyclic AMP inhibition of NF-κB mediated transcription. J Immunol 1997; 159: 5450-6.
• 33 Morandini R, Ghanem G, Portier-Lemarie A. et al. Action of cAMP on expression and release of adhesion molecules in human endothelial cells. Am J Physiol 1996; 270: H807-16.
• 34 Ghersa P, Hooft van Huijsduijnen R, Whelan J. et al. Inhibition of E-selectin gene transcription through a cAMP-dependent protein kinase pathway. J Biol Chem 1994; 269: 29129-37.